CCAM BIOTHERAPEUTICS

ccam-biotherapeutics-logo

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.

#SimilarOrganizations #People #Financial #Website #More

CCAM BIOTHERAPEUTICS

Industry:
Biotechnology Clinical Trials Therapeutics

Founded:
2009-01-01

Address:
Qiryat Shmona, HaZafon, Israel

Country:
Israel

Website Url:
http://www.ccam-bio.com

Total Employee:
11+

Status:
Closed

Contact:
972 4 681 8829

Email Addresses:
[email protected]

Total Funding:
0

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Nginx DigiCert SSL CloudFront Google Adsense AdBlock Acceptable Ads Google Adsense For Domains Thawte SSL


Similar Organizations

juno-therapeutics-logo

Juno Therapeutics

Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.

Current Employees Featured

gal-markel_image

Gal Markel
Gal Markel Founder and Chief Scientific Officer @ cCAM Biotherapeutics
Founder and Chief Scientific Officer

Founder


gal-markel_image

Gal Markel

Investors List

arkin-holdings_image

Arkin Holdings

Arkin Holdings investment in Series A - cCAM Biotherapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series A - cCAM Biotherapeutics

pontifax_image

Pontifax

Pontifax investment in Series A - cCAM Biotherapeutics

Official Site Inspections

http://www.ccam-bio.com

  • Host name: 104.21.48.1
  • IP address: 104.21.48.1
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "cCAM Biotherapeutics"

cCAM Biotherapeutics - Crunchbase Company Profile & Funding

Sep 15, 2012 cCAM Biotherapeutics is a pre-clinical stage company that develops immunotherapies for cancer.See details»

cCAM Biotherapeutics Company Profile 2024: Valuation, Investors ...

CCAM Biotherapeutics General Information Description. Developer of novel immunotherapies for different cancer indications. The company's lead agent is CM-10, an immunomodulatory โ€ฆSee details»

Merck Enhances Immuno-Oncology Portfolio with Acquisition of โ€ฆ

Jul 28, 2015 About cCAM Biotherapeutics. Founded in 2010 and led by Tehila Ben-Moshe, Ph.D., cCAM is a biopharmaceutical company focused on the discovery and development of โ€ฆSee details»

OBIO®

OBIO®, 108 College St., Suite W1020, Toronto, Ontario, Canada M5G 0C6 (416) 848 6839 [email protected]See details»

Merck Enhances Immuno-Oncology Portfolio acuiring cCAM

Jul 29, 2015 About cCAM Biotherapeutics Founded in 2010 and led by Tehila Ben-Moshe, Ph.D., cCAM is a biopharmaceutical company focused on the discovery and development of โ€ฆSee details»

cCAM Biotherapeutics - Foreign Startup | Startup Nation Finder

Apr 20, 2015 cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer. The company's lead product, CM โ€ฆSee details»

BIO Member Directory

The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please โ€ฆSee details»

BIO Appoints Veteran Communications Leader Sarah Alspach as โ€ฆ

16 hours ago Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications โ€ฆSee details»

cCAM Biotherapeutics Announces Initiation of Phase 1 Trial of CM โ€ฆ

Apr 23, 2015 Dr. Tehila Ben-Moshe, Chief Operation Officer, cCAM Biotherapeutics, stated, "We are pleased to have our CM-24 Phase 1 clinical trial underway.See details»

About BIO 2025 - BIO International Convention 2024

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. Whether you work at a public pharmaceutical โ€ฆSee details»

OmniaBio Inc. Launch Announcement - CCRM

MaRS Centre, West Tower 661 University Avenue, Suite 1002 Toronto, Ontario M5G 1M1 Canada t: 416-978-3751 f: 416-978-1368See details»

Merck Enhances Immuno-Oncology Portfolio with Acquisition of โ€ฆ

Jul 28, 2015 "Merck's excellence and leadership in immuno-oncology provides a strong foundation for advancing CM-24, for the treatment of people with cancer," said Pini Orbach, โ€ฆSee details»

OmniaBioโ€™s Impact and Future with Mitchel Sivilotti

Apr 27, 2024 Mitch Sivilotti, CEO of OmniaBio Inc., shared with CanadianSME Small Business Magazine how OmniaBio is propelling Canada to the forefront of cell and gene therapy (CGT) โ€ฆSee details»

Climate Change Adaptation and Mitigation (CCAM) Team Leader

Oct 13, 2022 ICBA is seeking a Climate Change Adaptation and Mitigation (CCAM) Team Leader to join the Sustainable Natural Resources Management (SNRM) unit to accelerate the โ€ฆSee details»

CCRM | Commercializing Living Therapies

CCRM is a catalyst for commercializing regenerative medicine-based technologies and cell and gene therapies. We enable product development through the unique translational platforms โ€ฆSee details»

OmniaBio Inc. - CCRM

Organization (CDMO) for the manufacture of cell and gene therapies. OmniaBio will provide pivotal/Phase III and commercial-scale manufacturing of gene-modified cells and viral vectors โ€ฆSee details»

OmniaBio, CCRM and Stakeholders Celebrate Commencement of โ€ฆ

October 6, 2022 (Hamilton, ON) โ€“ OmniaBio Inc., a commercial-stage contract development and manufacturing organization (CDMO) focused on cell and gene therapies (CGTs), has broken โ€ฆSee details»

CCAM: Cooperative, connected & automated mobility - SWARCO

CCAM โ€“ i.e. cooperative, networked and automated mobility โ€“ will permanently change the traffic of the future and is one of the major future trends in the automotive industry.By gradually โ€ฆSee details»

OmniaBio: Bringing Maturity to Cell and Gene Therapy (Drone Video)

MaRS Centre, West Tower 661 University Avenue, Suite 1002 Toronto, Ontario M5G 1M1 Canada t: 416-978-3751 f: 416-978-1368See details»

About Us - CCRM

By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services โ€ฆSee details»

linkstock.net © 2022. All rights reserved